Literature DB >> 14961029

Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program.

V H J van der Velden, N Boeckx, M Gonzalez, M Malec, G Barbany, T Lion, E Gottardi, N Pallisgaard, E Beillard, W C J Hop, P G Hoogeveen, J Gabert, J J M van Dongen.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 14961029     DOI： 10.1038/sj.leu.2403309

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Development and evaluation of armored RNA-based standards for quantification of BCR-ABL1p210/p190 fusion gene transcripts.

Authors:  Yu Fu; Rui Zhang; Qisheng Wu; Jiawei Zhang; Lihua Bao; Jinming Li
Journal:  J Clin Lab Anal       Date:  2018-06-29       Impact factor: 2.352

2.  beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia.

Authors:  Joong Won Lee; Qiaofang Chen; Daniel M Knowles; Ethel Cesarman; Y Lynn Wang
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

3.  Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples.

Authors:  Lauren M Stanoszek; Erin L Crawford; Thomas M Blomquist; Jessica A Warns; Paige F S Willey; James C Willey
Journal:  J Mol Diagn       Date:  2013-03-27       Impact factor: 5.568

Review 4.  Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Authors:  Michaela Kotrova; Jan Trka; Michael Kneba; Monika Brüggemann
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

Review 5.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

6.  Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARα transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.

Authors:  Mohieddin Barzegar; Mehdi Allahbakhshian Farsani; Mohammad Rafiee; Vahid Amiri; Sayeh Parkhihdeh; Fariba Rad; Mohammad Hossein Mohammadi
Journal:  Ann Hematol       Date:  2021-07-08       Impact factor: 3.673

Review 7.  [Linear B-cell epitope prediction].

Authors:  Ia I Davydov; A G Tonevitskiĭ
Journal:  Mol Biol (Mosk)       Date:  2009 Jan-Feb

8.  Establishment of a standardized multiplex assay with the analytical performance required for quantitative measurement of BCR-ABL1 on the international reporting scale.

Authors:  J T Brown; W Laosinchai-Wolf; J B Hedges; C D Watt; V M Van Deerlin; L Fletcher; S Branford; E Labourier
Journal:  Blood Cancer J       Date:  2011-03-25       Impact factor: 11.037

9.  BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.

Authors:  Ilaria S Pagani; Phuong Dang; Ivar O Kommers; Jarrad M Goyne; Mario Nicola; Verity A Saunders; Jodi Braley; Deborah L White; David T Yeung; Susan Branford; Timothy P Hughes; David M Ross
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

10.  Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia.

Authors:  S Ganesan; A A Alex; E Chendamarai; N Balasundaram; H K Palani; S David; U Kulkarni; M Aiyaz; R Mugasimangalam; A Korula; A Abraham; A Srivastava; R A Padua; C Chomienne; B George; P Balasubramanian; V Mathews
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.